Assumpta Nakintu Maria
ID:
|
OTITIS MEDIA WITH EFFUSION AND ITS ASSOCIATED FACTORS AMONG PATIENTS WITH CEREBRAL PALSY BETWEEN 2 TO 18 YEARS AT MULAGO AND KAWEMPE NATIONAL REFERRAL HOSPITALS REC NO.2021-180
REFNo: HS1958ES
To determine the burden and factors associated with otitis media with effusion among patients between 2 to 18 years with cerebral palsy at Mulago and Kawempe National Referral Hospitals,To determine the factors associated with otitis media with effusion among patients beween 2 to 18 years with cerebral palsy at Mulago and Kawempe National Referral Hospitals,To determine the prevalence of otitis media with effusion among patients between 2 to 18 years with cerebral palsy at Mulago and Kawempe National Referral Hospitals,
|
Uganda |
2022-01-05 |
2025-01-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Emmy Okello
ID: UNCST-2020-R009792
|
A Long-Term Follow-up Study for Patients Who
Participated in the GOAL Trial (GOAL-Post)
REFNo: HS1975ES
Primary Objective: To assess whether children who completed the GOAL trial and now have normal
echocardiograms have the same risk for progression as a new group of age/sex matched controls who
have a normal echocardiogram at study entry.
Secondary Objectives: To determine the 5-year rates of RHD progression among children with
persistent latent RHD who receive every-4-week BPG prophylaxis (durability of the intervention to
prevent RHD progression).
Tertiary Objective: To create a biobank that will support future research on RHD genetic
predisposition.
|
Uganda |
2022-01-05 |
2025-01-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
FREDDIE SSENGOOBA Peter
ID: UNCST-2021-R011834
|
An Assessment of Health Facility and District Autonomy, Income, and Expenditures in Uganda
REFNo: HS1985ES
To document and assess the de jure versus de facto autonomy levels for fiscal and operational decision making; de jure versus de facto use, reporting and accounting mechanisms of available resources; and the purchasing arrangements and expenditure reporting mechanisms that have been put in place for COVID-19 related activities and services at the district and facility levels in Uganda.
|
Uganda |
2022-01-05 |
2025-01-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Andrew Mujugira
ID: UNCST-2019-R000871
|
Implementation science research on PrEP delivery and costing within harm reduction services for people who use drugs in Uganda.
REFNo: HS1744ES
Aim 1. To compare PrEP uptake, retention, and adherence when PrEP is delivered through
community-based NSP versus facility-based MAT to PWUD.
Brief approach. We will integrate PrEP delivery into the first-ever MAT program in Kampala
(facility-based model) and a community-based NSP program. We will work with
community advocates for PWUD to recruit 150 people per program and compare uptake
of PrEP, retention, and objective measures of PrEP adherence (plasma tenofovir) during
one year of follow-up.
Aim 1a. To measure the impact of knowledge gained from training peers of PWUD on PrEP.
Brief approach. We will train up to 50 health care providers of PWUD on PrEP service
delivery using the national curriculum on PrEP services delivery. We will administer a
quantitative assessment of PrEP knowledge and experiences with service provision at
three time points: 1. Before the training (Baseline survey), 2. immediately after training
(Post training survey), and 3. ~3 months post training (Exit survey).
Aim 2. To estimate the programmatic costs and conduct budget impact analysis for
integrating PrEP into MAT and NSP programs.
Brief approach. We will conduct costing and budget impact analyses, including estimating
costs incurred for people who elect to not use PrEP, to guide approaches for intervention
scale-up
|
Uganda |
2022-01-03 |
2025-01-03 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Halid Kirunda
ID:
|
Evaluation of efficacy and safety of AMITRANOR® in tick control in Uganda
REFNo: HS1947ES
1. Determine the in vitro efficacy of AMITRANOR® on the main cattle ticks in Uganda.
2. Determine the “knockdown” effect of AMITRANOR® on ticks on cattle.
3. Enumerate any adverse effects of AMITRANOR® among experimental cattle.
|
Uganda |
2022-01-03 |
2025-01-03 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|